Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With scpJAK/scp Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Journal:
Arthritis & Rheumatology
Published:
DOI:
10.1002/art.43188
Affiliations:
24
Authors:
29
Institutions Authors Share
Geneva University Hospitals (HUG), Switzerland
6.000000
0.21
Karolinska Institute (KI), Sweden
2.000000
0.07
University General Hospital of Heraklion (PAGNI), Greece
2.000000
0.07
Diakonhjemmet Hospital, Diakonhjemmet Foundation, Norway
2.000000
0.07
HUS Helsinki University Hospital, Finland
2.000000
0.07
Institute of Rheumatology, Czech Republic
2.000000
0.07
German Rheumatism Research Centre Berlin (DRFZ), Germany
1.500000
0.05
New University of Lisbon (UNL), Portugal
1.500000
0.05
Physiology and Experimental Medicine: Heart - Muscles (PHYMEDEXP), France
1.000000
0.03
Carol Davila University of Medicine and Pharmacy (UMFCD), Romania
1.000000
0.03
NIHR Manchester Biomedical Research Centre (Manchester BRC), United Kingdom (UK)
1.000000
0.03
University of Bari Aldo Moro (UniBA), Italy
1.000000
0.03
Austrian Registry for Biologicals, Biosimilars, and Targeted Synthetic DMARDS (BioReg), Austria
1.000000
0.03
Spanish Society of Rheumatology (SER), Spain
1.000000
0.03
Manchester Academic Health Science Centre (MAHSC), United Kingdom (UK)
1.000000
0.03
Institut de recherche en rhumatologie de Montréal, Canada
0.500000
0.02
Hospital of the University of Montreal (CHUM), Canada
0.500000
0.02
Reuma.pt - Sociedade Portuguesa de Reumatologia, Portugal
0.500000
0.02
University of Ljubljana, Slovenia
0.500000
0.02
Ljubljana University Medical Centre (Ljubljana UMC), Slovenia
0.500000
0.02
Charité - University Medicine Berlin, Germany
0.500000
0.02